NICE widens prescribing options for Mabthera, but Roche unlikely to see big impact
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has published final draft guidance that recommends expanding the use of Roche's Mabthera (rituximab) to include further chemotherapy regimens for the first-line treatment of stage III-IV follicular lymphoma. It seems that NICE is playing catch up and bringing clinical practice into line with other countries.